Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 7, 2014, Pages

  Ellero Simatos, S ^a,b   Lewis, J P ^c   Georgiades, A ^d   Yerges Armstrong, L M ^c   Beitelshees, A L ^c   Horenstein, R B ^c   Dane, A ^a,b   Harms, A C ^a,b   Ramaker, R ^a,b   Vreeken, R J ^a,b   Perry, C G ^c   Zhu, H ^d   Sanchez C L ^d,e   Kuhn, C ^d   Ortel, T L ^d   Shuldiner, A R ^c   Hankemeier, T ^a,b   Kaddurah Daouk, R ^f,g  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Netherlands Metabolomics Centre   (Netherlands)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; COLLAGEN; SEROTONIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; DRUG BLOOD LEVEL; EX VIVO STUDY; FEMALE; HUMAN; INCUBATION TIME; MALE; MASS SPECTROMETRY; METABOLOMICS; NORMAL HUMAN; PHARMACOMETABOLOMICS; PLATELET REACTIVITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THROMBOCYTE; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

EID: 84905390793     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.22     Document Type: Article

References (48)

1. Amin, A.R., Attur, M.G., Pillinger, M. & Abramson, S.B. The pleiotropic functions of aspirin: mechanisms of action. Cell. Mol. Life Sci. 56, 305-312 (1999).
2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention ofb death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
3. Hovens, M.M., Snoep, J.D., Eikenboom, J.C., van der Bom, J.G., Mertens, B.J. & Huisman, M.V. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am. Heart J. 153, 175-181 (2007).
4. Gum, P.A., Kottke-Marchant, K., Welsh, P.A., White, J. & Topol, E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 41, 961-965 (2003).
5. Patrignani, P., Filabozzi, P. & Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69, 1366-1372 (1982).
6. Frelinger, A.L.3rd, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 120, 2586-2596 (2009).
7. Eikelboom, J.W. et al.; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 118, 1705-1712 (2008).
8. Ohmori, T. et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J. Thromb. Haemost. 4, 1271-1278 (2006).
9. Hankey, G.J. & Eikelboom, J.W. Aspirin resistance. Lancet 367, 606-617 (2006).
10. Clayton, T.A. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
11. Nicholson, J.K., Wilson, I.D. & Lindon, J.C. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12, 103-111 (2011).
12. Kaddurah-Daouk, R. et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One 6, e25482 (2011).
13. Kaddurah-Daouk, R. et al. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 6, 191-201 (2010).
14. Trupp, M. et al. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS One 7, e38386 (2012).
15. Wikoff, W.R. et al.; Pharmacometabolomics Research Network. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One 8, e57639 (2013).
16. Ji, Y. et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics- informed pharmacogenomics. Clin. Pharmacol. Ther. 89, 97-104 (2011).
17. Kaddurah-Daouk, R. et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl. Psychiatry 1, (2011).
18. Clayton, T.A., Baker, D., Lindon, J.C., Everett, J.R. & Nicholson, J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. U. S. A. 106, 14728-14733 (2009).
19. Sabatine, M.S. et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112, 3868-3875 (2005).
20. Shah, S.H. et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ. Cardiovasc. Genet. 3, 207-214 (2010).
21. van Velzen, E.J. et al. Multilevel data analysis of a crossover designed human nutritional intervention study. J. Proteome Res. 7, 4483-4491 (2008).
22. Ingebretsen, O.C., Bakken, A.M. & Farstad, M. Liquid chromatography of serotonin and adenine nucleotides in blood platelets, illustrated by evaluation of functional integrity of platelet preparations. Clin. Chem. 31, 695-698 (1985).
23. Li, N., Wallén, N.H., Ladjevardi, M. & Hjemdahl, P. Effects of serotonin on platelet activation in whole blood. Blood Coagul. Fibrinolysis 8, 517-523 (1997).
24. Walther, D.J. et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 115, 851-862 (2003).
25. Yerges-Armstrong, L.M. et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 94, 525-532 (2013).
26. Needs, C.J. & Brooks, P.M. Clinical pharmacokinetics of the salicylates. Clin. Pharmacokinet. 10, 164-177 (1985).
27. Walther, D.J. & Bader, M. A unique central tryptophan hydroxylase isoform. Biochem. Pharmacol. 66, 1673-1680 (2003).
28. Furness, J.B. & Costa, M. Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: their projections in the guinea-pig small intestine. Neuroscience 7, 341-349 (1982).
29. Killam, A.L. & Cohen, M.L. Characterization of rat platelet serotonin receptors with tryptamine agonists and the antagonists: ketanserin and SCH 23390. Thromb. Res. 64, 331-340 (1991).
30. Ziu, E. et al. Down-regulation of the serotonin transporter in hyperreactive platelets counteracts the pro-thrombotic effect of serotonin. J. Mol. Cell. Cardiol. 52, 1112-1121 (2012).
31. Hergovich, N., Aigner, M., Eichler, H.G., Entlicher, J., Drucker, C. & Jilma, B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin. Pharmacol. Ther. 68, 435-442 (2000).
32. Bismuth-Evenzal, Y., Gonopolsky, Y., Gurwitz, D., Iancu, I., Weizman, A. & Rehavi, M. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J. Affect. Disord. 136, 99-103 (2012).
33. Sauer, W.H., Berlin, J.A. & Kimmel, S.E. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 104, 1894-1898 (2001).
34. Schlienger, R.G. & Meier, C.R. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction? Am. J. Cardiovasc. Drugs 3, 149-162 (2003).
35. Labos, C., Dasgupta, K., Nedjar, H., Turecki, G. & Rahme, E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 183, 1835-1843 (2011).
36. Vikenes, K., Farstad, M. & Nordrehaug, J.E. Serotonin is associated with coronary artery disease and cardiac events. Circulation 100, 483-489 (1999).
37. Ueno, M., Kodali, M., Tello-Montoliu, A. & Angiolillo, D.J. Role of platelets and antiplatelet therapy in cardiovascular disease. J. Atheroscler. Thromb. 18, 431-442 (2011).
38. Macchi, L. et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb. Res. 107, 45-49 (2002).
39. Kawasaki, T., Ozeki, Y., Igawa, T. & Kambayashi, J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke. 31, 591-595 (2000).
40. Duerschmied, D. et al. Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study. PLoS One 7, e32656 (2012).
41. Harrison, P., Frelinger, A.L. 3rd, Furman, M.I. & Michelson, A.D. Measuring antiplatelet drug effects in the laboratory. Thromb. Res. 120, 323-336 (2007).
42. Snoep, J.D., Hovens, M.M., Eikenboom, J.C., van der Bom, J.G. & Huisman, M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167, 1593-1599 (2007).
43. Reny, J.L., De Moerloose, P., Dauzat, M. & Fontana, P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J. Thromb. Haemost. 6, 444-450 (2008).
44. Mitchell, B.D. et al. The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. Am. Heart J. 155, 823-828 (2008).
45. Shen, H. et al. Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). Am. J. Cardiol. 104, 606-612 (2009).
46. Xia, J., Psychogios, N., Young, N. & Wishart, D.S. MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res. 37, W652-W660 (2009).
47. Pinheiro, J. & Bates, D. Mixed-Effects Models in S and S-PLUS (Springer-Verlag, New York, 2000).
48. Storey, J.D. A direct approach to false discovery rates. J Roy Stat Soc. B. 64, 479-498 (2002).